2. Search Result
Search Result
Results for "

platinum

" in MedChemExpress (MCE) Product Catalog:

19

Inhibitors & Agonists

2

Biochemical Assay Reagents

2

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W034985
    Tetrakis(triphenylphosphine)platinum

    Tetrakis(triphenylphosphine)platinum(0)

    		 Biochemical Assay Reagents Others
    Tetrakis(triphenylphosphine)platinum is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    Tetrakis(triphenylphosphine)<em>platinum</em>
  • HY-109146
    Imifoplatin

    PT-112

    		 Apoptosis DNA Alkylator/Crosslinker Cancer
    Imifoplatin (PT-112) is a platinum-based agent belonging to the phosphaplatin family. Imifoplatin exhibits antineoplastic activity .
    Imifoplatin
  • HY-155012
    Mcl-1 inhibitor 16

    		Bcl-2 Family Cancer
    Mcl-1 inhibitor 16 (Compound 9) is a mitochondrial targeting Platinum-based inhibitor of Mcl-1. Mcl-1 inhibitor 1 induces Bax/Bak-dependent apoptosis in cancer cells. Mcl-1 inhibitor 16 can be used alone or together with ABT-199 (HY-15531) and shows anti-tumor activity .
    Mcl-1 inhibitor 16
  • HY-106588
    Heptaplatin

    SKI 2053R

    		 DNA Alkylator/Crosslinker Cancer
    Heptaplatin (SKI 2053R) is a platinum derivative with anticancer activity against various cancer cell lines, including cisplatin-resistant tumor cell lines. SKI-2053R is active in the research of gastric adenocarcinoma and has favorable toxicity profiles .
    Heptaplatin
  • HY-131468
    Picoplatin

    AMD473; ZD0473

    		 Others Cancer
    Picoplatin (AMD473) is a platinum-based antineoplastic agent. Picoplatin is specifically to circumvent thiol-mediated drug resistance by sterically hindering its reaction with glutathione (GSH) while still retaining the ability to form cytotoxic lesions with DNA .
    Picoplatin
  • HY-17394
    Cisplatin
    380+ Cited Publications

    cis-platinum; CDDP; cis-Diaminodichloroplatinum

    		 DNA Alkylator/Crosslinker Ferroptosis Autophagy Cancer
    Cisplatin (CDDP) is an antineoplastic chemotherapy agent by cross-linking with DNA and causing DNA damage in cancer cells. Cisplatin activates ferroptosis and induces autophagy .
    Cisplatin
  • HY-W112941
    (meso-Tetraphenylporphinato)platinum

    Pt(II) Meso-Tetraphenylporphine

    		 Biochemical Assay Reagents Others
    Meso- tetraphenylporphyrin - pt(ii) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    (meso-Tetraphenylporphinato)<em>platinum</em>
  • HY-139813
    Phenanthriplatin

    		DNA Alkylator/Crosslinker Cancer
    Phenanthriplatin is a monovalent platinum(II)-based complex with a large cytotoxicity against cancer cells .
    Phenanthriplatin
  • HY-129909
    Anticancer agent 173

    		Apoptosis Infection Cancer
    Anticancer agent 173 (compound 19) is a potent thioxodihydroquinazolinone analogs when combined with platinum drugs in inducing apoptotic cancer cells death .
    Anticancer agent 173
  • HY-17394R
    Cisplatin (Standard)

    cis-platinum (Standard); CDDP (Standard); cis-Diaminodichloroplatinum (Standard)

    		 DNA Alkylator/Crosslinker Ferroptosis Autophagy Cancer
    Cisplatin (Standard) is the analytical standard of Cisplatin. This product is intended for research and analytical applications. Cisplatin (CDDP) is an antineoplastic chemotherapy agent by cross-linking with DNA and causing DNA damage in cancer cells. Cisplatin activates ferroptosis and induces autophagy .
    Cisplatin (Standard)
  • HY-163383
    L-Ent-oxPt(IV)

    L-EOP

    		 Bacterial Infection
    L-Ent-oxPt IV (L-EOP) is a Oxaliplatin (HY-17371)-based siderophore-platinum conjugate. L-Ent-oxPt IV exhibits selectivity towards Escherichia coli and antibacterial activity through DNA damage .
    L-Ent-oxPt(IV)
  • HY-157222
    Antitumor agent-125

    		Others Cancer
    Antitumor agent-125 (compound 17A) is a novel platinum(IV) prodrug. Antitumor agent-125 can activate the mitochondrion-dependent apoptosis pathway. Antitumor agent-125 induces ferroptosis in HCT-116/OXA .
    Antitumor agent-125
  • HY-P99229
    Upifitamab

    		ADC Antibody Cancer
    Upifitamab is an ADC Antibody (a naked antibody of upifitamab rilsodotin), which can be used for antibody-coupled agent (ADC) synthesis. Upifitamab rilsodotin is an ADC targeting NaPi2b and is used in ovarian cancer research, particularly in platinum-resistant recurrent ovarian cancer .
    Upifitamab
  • HY-105930
    Lobaplatin
    2 Publications Verification

    D-19466

    		 Apoptosis Caspase Bcl-2 Family Cancer
    Lobaplatin (D-19466) is a diastereometric mixture of platinum(II) complexe. Lobaplatin arrests cell cycle at G1 and G2/M phase. Lobaplatin induces apoptosis by increasing expressions of caspase and Bax, decreasing expression of Bcl-2. Lobaplatin can be used for research of cancer .
    Lobaplatin
  • HY-151883
    APE1-IN-2

    		Apoptosis MDM-2/p53 Cancer
    APE1-IN-2 (compound AP1) is a Pt(IV) proagent, targeting a critical BER protein, apurinic/apyrimidinic endonuclease 1 (APE1). APE1-IN-2 shows anticancer activity. APE1-IN-2 induces intracellular accumulation of platinum and activates DNA damage response and apoptosis signals .
    APE1-IN-2
  • HY-155807
    DPP

    		STAT JAK Apoptosis Cancer
    DPP is a Platinum(IV) complex, bearing pterostilbene-derived axial ligand. DPP inhibit the JAK2-STAT3 pathway in breast cancer (BC) cells with antiproliferative activity, and activates caspase-3 and cleaved poly ADP-ribose polymerase to induces apoptosis. DPP promotes the maturation and antigen presentation of dendritic cells, and exhibits in vivo safety .
    DPP
  • HY-114842
    TDRL-551

    		Others Cancer
    TDRL-551 is a potent replication protein A (RPA) inhibitor (IC50=18 µM). TDRL-551 inhibits RPA-DNA interaction and increases the efficacy of Platinum (Pt)-based chemotherapy in lung and ovarian cancer. RPA plays essential roles in both nucleotide excision repair (NER) and homologous recombination (HR), along with its role in DNA replication and DNA damage checkpoint activation .
    TDRL-551
  • HY-155808
    STAT3-IN-18

    		STAT JAK Apoptosis COX Cancer
    STAT3-IN-18 (compound SPP) is a platinum (IV) complex with an axial ligand derived from sandalwood. STAT3-IN-18 inhibits the JAK2-STAT3 pathway in breast cancer (BC) cells, with anti-proliferative activity. STAT3-IN-18 activates caspase-3 and increases cleaved polyADP-ribose polymerase to induce apoptosis. STAT3-IN-18 promotes maturation and antigen presentation of dendritic cells and demonstrates safety in vivo.
    STAT3-IN-18
  • HY-P99463
    Batiraxcept

    AVB-S6-500

    		 TAM Receptor Cancer
    Batiraxcept (AVB-S6-500) is a highly potent and specific AXL inhibitor, a recombinant fusion protein dimer containing the extracellular domain of human AXLM and human immunoglobulin G1 heavy chain (Fc). Batiraxcept binds to GAS6 and inhibits the interaction of GAS6 with AXL, thereby substantially reducing AXL signaled invasion and migration of highly metastatic cells in vitro and inhibiting metastatic disease in nonclinical models of aggressive human cancers. Batiraxcept is available for studies in advanced or metastatic clear cell renal cell carcinoma (ccRCC) and platinum sensitive recurrent ovarian cancer .
    Batiraxcept

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: